Topos Bio, Inc.
- Biotech or pharma, therapeutic R&D
We’re developing an AI-powered drug discovery platform specifically designed to tackle Intrinsically Disordered Proteins (IDPs)—a class of targets long considered “undruggable.” IDPs represent at least 30% of the human proteome, are notoriously difficult to model with current AI tools like AlphaFold, and are implicated in a wide range of diseases.
Our platform combines state-of-the-art computational methods with robust experimental validation to rationally design therapeutics across neurodegeneration, oncology, and metabolic disease. While modality-agnostic, we focus heavily on small molecules, peptides, and targeted protein degraders.
We’re actively seeking partners who share our vision of overcoming these high-value, historically intractable targets through a best-in-class, AI-driven approach.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}